Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis
Shots:
- The P-III OPTIMUM study involves assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide- 14mg) in 1-133 patients with relapsing multiple sclerosis for 108 weeks
- The study resulted in meeting 1 EPs of annualized relapse rate (ARR) up to the end of the study and most of its 2 EPs with no new observed signals
- Ponesimod is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator- inhibiting S1P activity and reduces the number of circulating lymphocytes with its anticipated EMA’s approval for relapsing MS in H2’19
Click here to read full press release/ article
Ref: Janssen | Image: Janssen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com